Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages

Shares of Nkarta, Inc. (NASDAQ:NKTX) have earned an average rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $15.00.

Several analysts have issued reports on the stock. Rodman & Renshaw assumed coverage on shares of Nkarta in a research report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price target on the stock. Mizuho reduced their price objective on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research report on Thursday, November 21st. HC Wainwright cut their target price on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, November 11th. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. Finally, Needham & Company LLC dropped their price objective on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 8th.

Nkarta Trading Up 14.6 %

NKTX opened at $2.99 on Thursday. Nkarta has a 1-year low of $2.38 and a 1-year high of $16.24. The business has a 50 day moving average of $3.63 and a 200-day moving average of $5.17. The stock has a market capitalization of $211.00 million, a price-to-earnings ratio of -1.59 and a beta of 0.86.

Hedge Funds Weigh In On Nkarta

Institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. acquired a new stake in shares of Nkarta during the third quarter worth approximately $151,000. Barclays PLC grew its position in Nkarta by 161.4% during the 3rd quarter. Barclays PLC now owns 232,566 shares of the company’s stock worth $1,051,000 after acquiring an additional 143,608 shares during the last quarter. Geode Capital Management LLC increased its holdings in Nkarta by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock valued at $5,294,000 after purchasing an additional 33,927 shares in the last quarter. XTX Topco Ltd acquired a new stake in Nkarta during the 3rd quarter valued at $223,000. Finally, Wellington Management Group LLP raised its position in Nkarta by 24.8% in the 3rd quarter. Wellington Management Group LLP now owns 216,341 shares of the company’s stock valued at $978,000 after purchasing an additional 43,035 shares during the last quarter. 80.54% of the stock is owned by institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.